Work

The Intrauterine Device: How to Deploy This Strategy in the Molecular World?

Year: 2024

Type: article

Abstract: Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-24-2034

Authors: Paul Johannet, Claire F. Friedman

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute